Inclusion-body myositis
Targetsdruggable targets explored
Build the foundation
We mapped demographics, mechanisms and shared pathways with Alzheimer’s disease to find druggable targets.
Case Study · Strategic Landscaping
Three research areas, one pipeline strategy.
A global biopharma company wanted to sharpen pipeline decisions in inclusion-body myositis, AI/ML for computational chemistry and acute myeloid leukemia. Prescouter ran a dedicated landscape study for each, highlighting opportunities and partners.
The Client
The client is a global biopharma company. It wanted to advance its pipeline and strategic decisions across several areas of interest.
The Challenge
Three distinct areas.
One set of priorities.
The client needed comprehensive landscape evaluations to find emerging opportunities, potential collaborators and actionable insights aligned with its broader research and development goals.
-
Disease
Mechanisms and targets
The foundations of each disease.
-
Competition
Who is doing what
Programs, modalities and deals.
-
Opportunity
Where to engage
Partners, investments, acquisitions.
Our Approach
A dedicated study for each area.
AI/ML platforms
Dealspartnerships analyzed
Read the market
We compared AI/ML drug discovery players and analyzed their pharma partnerships by size and structure.
Acute myeloid leukemia
Emergingtargets and programs
Spot the next wave
We assessed targeted therapies, biologics and Menin inhibitors, plus early programs worth partnering on.
The Outcome
Landscapes that turn into actionable roadmaps.
Prescouter delivered detailed landscapes of inclusion-body myositis, acute myeloid leukemia and AI/ML computational platforms for drug discovery, with strategic recommendations for internal research priorities and external innovation. Intelligence Briefs, dynamic reports and supporting materials help the client benchmark assets, find gaps and pursue collaborations or acquisitions.
-
Roadmaps
Internal research priorities
Recommendations to advance them.
-
External
Collaboration targets
Partners and acquisition options.
-
Position
Assets benchmarked
Gaps and differentiation identified.
Pipeline decisions are only as good as the landscape behind them. Seeing mechanisms, competitors and deal patterns side by side makes the next move clearer.
Let’s Talk
Where should your pipeline go next?
Build the disease and technology landscapes that turn research priorities into clear pipeline decisions. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]